| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 03/18/2004 | CA2536010A1 Boronic acid salts useful in parenteral formulations for selective thrombin inhibition |
| 03/18/2004 | CA2535792A1 Boronic acid salts ant their use in the treatment of thrombosis |
| 03/18/2004 | CA2535788A1 Multivalent metal salts of boronic acids for treating thrombosis |
| 03/18/2004 | CA2501924A1 Non-nucleoside reverse transcriptase inhibitors |
| 03/18/2004 | CA2499380A1 Novel vinyl carboxylic acid derivatives and their therapeutical use |
| 03/18/2004 | CA2498297A1 Recombinatant mutants of rhabdovirus and methods of use thereof |
| 03/18/2004 | CA2497979A1 1, 3-diamino-2-hydroxypropane prodrug derivatives |
| 03/18/2004 | CA2497975A1 Combined immediate release and extended release analgesic composition |
| 03/18/2004 | CA2497970A1 Pyrazolopyridines and methods of making and using the same |
| 03/18/2004 | CA2497968A1 Imidazolopyridines and methods of making and using the same |
| 03/18/2004 | CA2497955A1 Medicament for preventing and/or treating inflammatory bowel disease |
| 03/18/2004 | CA2497951A1 Treatment of pain by inhibition of p38 map kinase |
| 03/18/2004 | CA2497896A1 Pravastatin pharmaceutical formulations and methods of their use |
| 03/18/2004 | CA2497892A1 Compositions and methods for tissue specific or inducible inhibition of gene expression |
| 03/18/2004 | CA2497873A1 Novel diagnostic and therapeutic methods and reagents therefor |
| 03/18/2004 | CA2497867A1 Delivery of modulators of glutamate-mediated neurotransmission to the inner ear |
| 03/18/2004 | CA2497836A1 A method of modulating endothelial cell activity |
| 03/18/2004 | CA2497832A1 Pharmaceuticals formulations and methods for modified release of statin drugs |
| 03/18/2004 | CA2497829A1 Method to treat allergic rhinitis |
| 03/18/2004 | CA2497828A1 A method of extending the dose range of vitamin d compounds |
| 03/18/2004 | CA2497827A1 (1h-benzoimidazol-2-yl)-(piperazinyl)-methanone derivatives and related compounds as histamine h4-receptor antagonists for the treatment of inflammatory and allergic disorders |
| 03/18/2004 | CA2497824A1 Use of a sri and vitamin b6 for the treatment of neurological and mental disorders |
| 03/18/2004 | CA2497823A1 Repair of dna mutagenic damage |
| 03/18/2004 | CA2497792A1 Cyclodextrin-based polymers for therapeutics delivery |
| 03/18/2004 | CA2497788A1 Use of histamine h4 receptor modulators for the treatment of allergy and asthma |
| 03/18/2004 | CA2497771A1 Polyethylene glycol cleansers useful for removing irritating compounds from bodily surfaces |
| 03/18/2004 | CA2497717A1 Compositions comprising microspheres with anti-inflammatory properties for healing of ocular tissues |
| 03/18/2004 | CA2497552A1 Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy |
| 03/18/2004 | CA2497497A1 Regulators for implantation |
| 03/18/2004 | CA2497464A1 A therapeutic agent for improving hypogastric and/or perineal pains |
| 03/18/2004 | CA2497437A1 Purine nucleosides as anti-apoptotic agents |
| 03/18/2004 | CA2497406A1 Short interfering nucleic acid hybrids and methods thereof |
| 03/18/2004 | CA2497374A1 Treatment of non-allergic rhinitis by means of selective phosphodiesterase-4 inhibitors |
| 03/18/2004 | CA2497350A1 Decoy-oligonucleotide-inhbition of cd40-expression |
| 03/18/2004 | CA2497335A1 Formulation for funnelling nucleic acids into eukaryotic cells |
| 03/18/2004 | CA2497246A1 Neoadjuvant treatment of breast cancer |
| 03/18/2004 | CA2497180A1 Treatment of metastatic breast cancer with anthracyclines, taxanes and an histamine antagonist |
| 03/18/2004 | CA2497164A1 Non-psychotropic cannabinoids for prevention of cognitive impairment |
| 03/18/2004 | CA2495939A1 Cathepsin cysteine protease inhibitors |
| 03/18/2004 | CA2495899A1 Solid nano pharmaceutical formulation and preparation method thereof |
| 03/18/2004 | CA2495442A1 Backbone-substituted bifunctional dota ligands, complexes and compositions thereof, and methods of using same |
| 03/18/2004 | CA2495284A1 Diarylurea derivatives and their use as chloride channel blockers |
| 03/18/2004 | CA2495043A1 Depigmenting composition for the skin comprising adapalene and at least one depigmenting agent |
| 03/18/2004 | CA2493974A1 Pharmaceutical dosage form comprising a sulfite compound |
| 03/18/2004 | CA2493723A1 Methods of treatment of male erectile dysfunction |
| 03/18/2004 | CA2441469A1 Methods and compositions for treating alzheimer's disease |
| 03/17/2004 | EP1398379A2 Compounds for immunotherapy and diagnosis of tuberculosis |
| 03/17/2004 | EP1398377A1 Growth differentation Factor-7 |
| 03/17/2004 | EP1398369A1 Bifidobacteria and preparations containing them |
| 03/17/2004 | EP1398315A1 Anti-inflammatory oxo-derivatives and hydroxy derivatives of pyrrolizines, and their pharmaceutical use |
| 03/17/2004 | EP1398040A1 Medicinal composition |
| 03/17/2004 | EP1398036A1 Ganoderma lucidum spores for treatment of autoimmune diseases |
| 03/17/2004 | EP1398033A2 Use of benzodiazepines for treating autoimmune diseases, inflammations, neoplasies, viral infections and atherosclerosis |
| 03/17/2004 | EP1398031A1 Use of 6-amino-quinoline-5,8-quinones and nucleic acids associated with senescence for the treatment of tumors |
| 03/17/2004 | EP1398030A2 Dipeptidyl peptidase IV effectors |
| 03/17/2004 | EP1398028A2 Taxanes having alkoxy, alkenoxy or aryloxy substituted side-chain and pharmaceutical compositions containing same |
| 03/17/2004 | EP1398027A1 Use of matrix metalloproteinase inhibitors for treating or preventing glomerulopathy |
| 03/17/2004 | EP1398026A2 The use of 2,3-dimethoxy-5-methyl-6-decaprenyl-1,4-benzoquinone |
| 03/17/2004 | EP1398024A2 Uses for thyroid hormone compounds |
| 03/17/2004 | EP1397957A2 Betulinic acid derivatives and uses therefor |
| 03/17/2004 | EP1397507A1 Methods and compositions for treating cardiovascular disease using 10218 |
| 03/17/2004 | EP1397503A2 Neuroblastoma cell lines expressing the alpha2delta subunit of calcium channels and methods therefore |
| 03/17/2004 | EP1397489A2 Tissue-specific and pathogen-specific toxic agents, ribozymes, dnazymes and antisense oligonucleotides, and methods of use thereof |
| 03/17/2004 | EP1397486A2 Polymorphisms in the human gene for cytochrome p450 polypeptide 2c8 and their use in diagnostic and therapeutic applications |
| 03/17/2004 | EP1397429A1 Composite particles, derived conjugates, preparation method thereof and applications of same |
| 03/17/2004 | EP1397387A1 Antibodies specific for cd44v6 |
| 03/17/2004 | EP1397382A2 Novel estrogen receptor ligand binding domain variants and novel ligands and pharmaceutical compositions |
| 03/17/2004 | EP1397379A1 Adenosine derivative in polymorph i form |
| 03/17/2004 | EP1397378A1 Adenosine derivative in polymorph ii form |
| 03/17/2004 | EP1397374A2 Siglec inhibitors |
| 03/17/2004 | EP1397370A1 B-benzyloxyaspartate derivatives with amino group on benzene ring |
| 03/17/2004 | EP1397369A1 New use or cyclolignans and new cyclolignans |
| 03/17/2004 | EP1397368A1 New use of specific cyclolignans |
| 03/17/2004 | EP1397366A1 Novel ligand for nicotinic acetylcholine receptors useful in therapy |
| 03/17/2004 | EP1397365A1 Novel heteroaryl-diazabicyclo-alkanes as cns-modulators |
| 03/17/2004 | EP1397364A1 Novel pyrrole derivatives as pharmaceutical agents |
| 03/17/2004 | EP1397363A1 5-ethyl-imidazotriazinones |
| 03/17/2004 | EP1397361A1 Carboline derivatives as pdev inhibitors |
| 03/17/2004 | EP1397360A1 Azaindoles |
| 03/17/2004 | EP1397359A1 1-biaryl-1,8-napthyridin-4-one phosphodiesterase-4 inhibitors |
| 03/17/2004 | EP1397358A1 Tropane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
| 03/17/2004 | EP1397357A2 Polymorphic forms of 1-'4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride |
| 03/17/2004 | EP1397356A1 Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (pai-1) |
| 03/17/2004 | EP1397355A1 Pyridyl cyanoguanidine compounds |
| 03/17/2004 | EP1397354A1 Imidazole-2-carboxamide derivatives as raf kinase inhibitors |
| 03/17/2004 | EP1397351A1 Pyrimidine, triazine and pyrazine derivatives as glutamate receptors |
| 03/17/2004 | EP1397350A1 Isoquinolinone derivatives as parp inhibitors |
| 03/17/2004 | EP1397348A2 Factor xa inhibitor |
| 03/17/2004 | EP1397341A1 6-(aryl-amido or aryl-amidomethyl)-naphthalen-2-yloxy-acidic derivatives as inhibitors of plasminogen activator inhibitor type-1 (pai-1) |
| 03/17/2004 | EP1397340A2 Chemical compounds and pharmaceutical compositions as cathepsin s inhibitors |
| 03/17/2004 | EP1397339A1 (ethylene)-(propylene)-triaminepentaacetic acid derivatives, process for their production, and their use for the production of pharmaceutical agents |
| 03/17/2004 | EP1397327A2 DEUTERATED N-SUBSTITUTED AND $g(a)-SUBSTITUTED DIPHENYLALKOXY ACETIC ACID AMINO ALKYL ESTERS AND MEDICAMENTS CONTAINING THESE COMPOUNDS |
| 03/17/2004 | EP1397172A1 Safety shield system for prefilled syringes |
| 03/17/2004 | EP1397170A1 Safety shield system for prefilled syringes |
| 03/17/2004 | EP1397161A2 Compounds comprising an analgesic molecule linked to a vector that can vectorise said molecule through the hematoencephalic barrier and pharmaceutical compositions containing same |
| 03/17/2004 | EP1397160A1 Pharmaceutical composition including ace/nep inhibitors and bioavailability enhancers |
| 03/17/2004 | EP1397158A2 USE OF IgM ANTIBODIES AGAINST dsDNA IN SYSTEMIC LUPUS ERYTHEMATOSUS WITH NEPHRITIS |
| 03/17/2004 | EP1397153A2 Methods for protecting allogeneic islet transplant using soluble ctla4 mutant molecules |
| 03/17/2004 | EP1397151A2 Wnv core protein/capsid interacting protein and uses of the same |
| 03/17/2004 | EP1397148A2 Chromium/biotin treatment of dyslipidemia and diet-induced post prandial hyperglycemia |